Butterfly Network vs Recursion Pharmaceuticals

By valuation, Recursion Pharmaceuticals is the larger company at $2.2B versus $1.5B — a 1.5x difference. Size can also be measured by team: Butterfly Network employs 500-1000 people while Recursion Pharmaceuticals has 800 employees.

Butterfly Network has raised $700M in disclosed funding across 0 known rounds. Recursion Pharmaceuticals's funding history is not publicly available.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Recursion Pharmaceuticals's 65/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 20-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed.

Butterfly Network was founded first in 2011, giving it 2 years of additional market experience. Recursion Pharmaceuticals was founded later in 2013. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while Recursion Pharmaceuticals has approximately 800. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and Recursion Pharmaceuticals are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.